Beta 2 Microglobulin - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Beta 2 Microglobulin

The Experts below are selected from a list of 162 Experts worldwide ranked by ideXlab platform

Klaus Jochen Eichhorn – 1st expert on this subject based on the ideXlab platform

  • Adsorption and displacement of Beta2Microglobulin at solid/liquid interfaces
    Macromolecular Symposia, 1999
    Co-Authors: Carsten Werner, Martin Pilz, Grit Eberth, Anke Menning, Horst-dieter Lemke, Klaus Jochen Eichhorn

    Abstract:

    Adsorption of Beta2Microglobulin from aqueous solution onto unmodified and methylated silicon wafers and subsequent displacement of the small globular protein by fibrinogen were studied by spectroscopic ellipsometry, immunosorbent assays and atomic force microscopy. The results provide evidence that hydrophobicity of the substrate increases the maximum adsorbed amount of Beta2Microglobulin and the resistance of the adsorbed protein to displacement from the interface by competing species, respectively. Further, the dynamics of Beta2Microglobulin adsorption was found to induce significant differences in the degree of displacement achieved at given conditions. The observed variations in displacement behavior of adsorbed Beta2Microglobulin were interpreted based on information on the layer structure gained by atomic force microscopy. More compact and relatively smooth protein layers were formed on the hydrophobic surface corresponding to lower displacement by fibrinogen.

  • Adsorption and displacement of Beta2Microglobulin at solid/liquid interfaces
    Macromolecular Symposia, 1999
    Co-Authors: Carsten Werner, Martin Pilz, Grit Eberth, Anke Menning, Horst-dieter Lemke, Klaus Jochen Eichhorn

    Abstract:

    Adsorption of Beta2Microglobulin from aqueous solution onto unmodified and methylated silicon wafers and subsequent displacement of the small globular protein by fibrinogen were studied by spectroscopic ellipsometry, immunosorbent assays and atomic force microscopy. The results provide evidence that hydrophobicity of the substrate increases the maximum adsorbed amount of Beta2Microglobulin and the resistance of the adsorbed protein to displacement from the interface by competing species, respectively. Further, the dynamics of Beta2Microglobulin adsorption was found to induce significant differences in the degree of displacement achieved at given conditions. The observed variations in displacement behavior of adsorbed Beta2Microglobulin were interpreted based on information on the layer structure gained by atomic force microscopy. More compact and relatively smooth protein layers were formed on the hydrophobic surface corresponding to lower displacement by fibrinogen.

Grover Ak – 2nd expert on this subject based on the ideXlab platform

  • Serum Beta2 Microglobulin and C-reactive protein levels in acute adenovirus conjunctivits
    Acta Ophthalmologica, 2009
    Co-Authors: Ak Gupta, G. S. Sarin, M. D. Mathur, Grover Ak

    Abstract:

    Serum Beta2 Microglobulin and C-reactive protein levels were measured in 52 patients with acute adenovirus conjunctivitis and 58 healthy subjects, by ELISA technique. Serum Beta2 Microglobulin levels were found to be significantly increased while there was no change in C-reactive protein levels. Serum Beta2 Microglobulin levels closely paralleled the severity of the disease. The increased Beta2 Microglobulin level in serum showed a significant fall to normal level on clinical improvement. There was no difference in the serum Beta2 Microglobulin levels in virus-isolation positive and negative patients.

  • Serum Beta2 Microglobulin and C‐reactive protein levels in acute adenovirus conjunctivits
    Acta Ophthalmologica, 2009
    Co-Authors: Ak Gupta, G. S. Sarin, M. D. Mathur, Grover Ak

    Abstract:

    : Serum Beta2 Microglobulin and C-reactive protein levels were measured in 52 patients with acute adenovirus conjunctivitis and 58 healthy subjects, by ELISA technique. Serum Beta2 Microglobulin levels were found to be significantly increased while there was no change in C-reactive protein levels. Serum Beta2 Microglobulin levels closely paralleled the severity of the disease. The increased Beta2 Microglobulin level in serum showed a significant fall to normal level on clinical improvement. There was no difference in the serum Beta2 Microglobulin levels in virus-isolation positive and negative patients.

C A Coltman – 3rd expert on this subject based on the ideXlab platform

  • prognostic value of pretreatment serum Beta 2 Microglobulin in myeloma a southwest oncology group study see comments
    Blood, 1990
    Co-Authors: Brian G M Durie, D Stocknovack, Sydney E Salmon, Paul R Finley, J Beckord, J Crowley, C A Coltman

    Abstract:

    Six hundred twelve eligible, previously untreated patients with active multiple myeloma and at least some data available for analysis were entered into a randomized trial (Southwest Oncology Group [SWOG] Phase III myeloma study 8229/30), in which the prognostic significance of pretreatment serum Beta 2 Microglobulin levels was evaluated. Because there was no statistically significant survival difference between the alternating and syncopating VMCP/VBAP regimens, it was possible to evaluate serum Beta 2 Microglobulin for the total population all together. The serum Beta 2 Microglobulin measurements showed the highest significance of any prognostic factor, both in the bivariate and multivariate regression analyses. The median survival was 36 months for the 322 patients with pretreatment serum Beta 2 Microglobulin values of less than 6 micrograms/mL, as compared with a median survival of 23 months for the 225 patients with a Beta 2 level of greater than or equal to 6 mcg/mL (P less than .0001). The stepwise multiple regression model first contained serum Beta 2 Microglobulin, followed by serum albumin, serum calcium, age, and serum creatinine. Serum Beta 2 Microglobulin was highly correlated with stage: median values ranged from 3.7 micrograms/mL for stage IA, to 10.1 for stage IIIB. It was possible to stratify myeloma patients based on combinations of serum Beta 2 Microglobulin with both albumin and age, producing excellent separation of patients into low-, intermediate-, and high-risk categories. It is concluded that serum Beta 2 Microglobulin is the most powerful prognostic factor currently available for multiple myeloma and that it can be used alone or in combination with other variables for pretreatment stratification.